Laurence is a Managing Partner in Fund II and Fund III, leading investments and building companies. Laurence led the establishment of 5 new CTI portfolio companies: Dalcor, Ilkos, Precithera, Find Therapeutics, and Epitopea. Laurence also led the investments in Amolyt Pharma, enGene, Domain Therapeutics, Thryv Therapeutics, and Profound Medical. AstraZeneca acquired Amolyt Pharma in March 2024 for $1.05B. She is an active board director of Dalcor, Find Therapeutics, Epitopea and Domain Therapeutics. Laurence is active in the Canadian life sciences community. She is a board director of adMare BioInnovations and Liphorus, a spin-off from Montreal Clinical Institute.

Before joining CTI, Laurence served as a life sciences analyst covering the Canadian life sciences sector for over ten years. She was involved in numerous mergers and acquisitions and IPOs. Laurence also served as Vice-President of Business Development of Univalor, the TTO of Montreal’s university. She oversaw the execution of 55 licenses with the industry and the establishment of 8 new companies. Dr. Rulleau has a master’s in biology from The University du Quebec a Montreal (UQAM) and a Ph.D. from the University of Montreal executed at the Montreal Clinical Research Institute.

‍